Scientists at Dana-Farber have launched a clinical test of a blood-cancer drug in patients that have the COVID-19 virus. The test follows several case reports in which the drug, ibrutinib, appeared to protect against lung damage and respiratory distress caused by the novel virus.

The goal of the randomized trial is to determine if treatment with ibrutinib, compared with standard supportive care, can reduce patients’ need for supplemental oxygen – including mechanical ventilation – shorten hospital stays, and improve survival.

You can read more about this exciting new trial being run by Dr. Steven Treon in the latest edition of "Inside the Institute".